• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

Accelero Receives Authority Permit for SARS-CoV-2 Testing

Accelero Bioanalytics GmbH (“Accelero”) has received the authority permit for processing and analysis of SARS-CoV-2 in biological samples.

The Berlin State Office for Occupational Safety, Health Protection, and Technical Safety (LAGetSi) as well as the local Health Department in Treptow-Köpenick both allowed the processing and analysis of upper and lower respiratory specimen (swaps, sputum, bronchoalveolar lavage) via SARS-CoV-2 specific RT-PCR assays.

The company will also work on immunological assays for innate immune response monitoring like IgG and/or IgM detection and titer determination against SARS-CoV-2 in human serum.

Accelero can also provide FluoroSpot assays for direct and sensitive detection of IgG secreting cells in response to SARS-CoV-2 stimulation in vitro.

All services will be provided in full compliance to Good Laboratory Practice (GLP) regulations.

NOT FOR DIAGNOSTIC USE – FOR INFORMATION PURPOSES ONLY.

Please click hereto download the complete press release including a figure with SARS-CoV-2 RNA genomic organisation.

 

200323 SARS CoV 2 Genome

The figure shows the genomic organization of a SARS-CoV-2 RNA genome isolated and sequenced from a patient in a Japanese cruise ship (Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2/Hu/DP/Kng/19-027 RNA, complete genome. Acc. No. LC528233, Hishiki T et al, 29-FEB-2020).

Accelero can provide three different assay formats:
(1) Three RT-PCR assays published by Institut Pasteur, Paris, FRANCE, targeting the genes RdRp IP2, RdRp IP4 and E, respectively.
(2) Three RT-PCR assays published by the CDC, Atlanta, UNITED STATES, targeting the nucleocapsid phosphoprotein.
(3) Three RT-PCR assays published by the Charité, Berlin, GERMANY, targeting the genes RdRp and E, respectively.
A sample is supposed to be positive for SARS-CoV-2 only if all three consecutive assays give a positive signal within the assay acceptance criteria.

 

Last update of this page: 12-MAY-2020 by CL

Save
Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline